How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Dravet Syndrome Therapeutics Market
- By Therapeutic Approach: Antiepileptic Drugs (AEDs), Cannabidiol-based Therapies, Gene Therapy, Dietary Therapies (Ketogenic Diet), Supportive Care
- By Drug Class: Sodium Channel Blockers, GABAergic Agents, Cannabinoids, Neurosteroids, Other Adjunctive Therapies
- By Route of Administration: Oral, Intravenous, Intranasal, Transdermal
- By Patient Age Group: Pediatric, Adolescent, Adult
- By Treatment Line: First-line Therapy, Second-line Therapy, Adjunctive Therapy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antiepileptic Drugs (AEDs) leads By Therapeutic Approach at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Dravet Syndrome Therapeutics Market report
A complete, evidence-based study - 12 chapters and 118 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Approach 5
Drug Class 5
Route of Administration 4
Patient Age Group 3
Treatment Line 3
Companies profiled
Zogenix Inc.
Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)
UCB Pharma
Marinus Pharmaceuticals Inc.
GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
Eisai Co. Ltd.
Biogen Inc.
Pfizer Inc.
Novartis AG
Sunovion Pharmaceuticals Inc.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zogenix Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →UCB Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Marinus Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Eisai Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Biogen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novartis AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Sunovion Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,650M by 2033 · 6.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antiepileptic Drugs (AEDs)50.3
- Cannabidiol-based Therapies17.7
- Gene Therapy9.9
- Dietary Therapies (Ketogenic Diet)9.1
- Supportive Care13.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$322.6M → $529.9M · 6.4%
Europe$224.9M → $416.6M · 8.0%
Asia Pacific$205.3M → $320.7M · 5.7%
Latin America$127.1M → $215.1M · 6.8%
Middle East and Africa$97.8M → $162.9M · 6.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.712026
6.732027
6.742028
6.752029
6.762030
6.782031
6.792032
6.792033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zogenix Inc.17.6
- Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)21.1
- UCB Pharma10.1
- Marinus Pharmaceuticals Inc.5.2
- GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)8.5
- Eisai Co. Ltd.9.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Approach16.5%
Drug Class18.3%
Route of Administration21.9%
Patient Age Group19.1%
Treatment Line24.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.2
- Europe25.3
- Asia Pacific19.5
- Latin America13.1
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zogenix Inc. | 76 | 79 | 85 | 78 | 94 | 99 | 85 |
| Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals) | 85 | 88 | 85 | 83 | 82 | 72 | 83 |
| UCB Pharma | 74 | 63 | 66 | 70 | 87 | 69 | 72 |
| Marinus Pharmaceuticals Inc. | 61 | 80 | 59 | 63 | 64 | 79 | 68 |
| GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals) | 60 | 68 | 71 | 60 | 68 | 61 | 65 |
| Eisai Co. Ltd. | 58 | 61 | 67 | 52 | 46 | 49 | 56 |
| Biogen Inc. | 47 | 51 | 52 | 41 | 51 | 50 | 49 |
| Pfizer Inc. | 37 | 54 | 51 | 58 | 52 | 48 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zogenix Inc.
- Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)
- UCB Pharma
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zogenix Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals) | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| UCB Pharma | ✓ | ◐ | ◐ | ◐ | ✓ | − |
| Marinus Pharmaceuticals Inc. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals) | ◐ | ◐ | − | − | ◐ | ◐ |
| Eisai Co. Ltd. | − | ◐ | ✓ | − | − | − |
| Biogen Inc. | ◐ | − | ◐ | ◐ | − | − |
| Pfizer Inc. | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zogenix Inc.85
2Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)83
3UCB Pharma72
4Marinus Pharmaceuticals Inc.68
5GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)65
6Eisai Co. Ltd.56
7Pfizer Inc.50
8Biogen Inc.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Zogenix Inc.Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)
Challenger2
Strong scale, closing on the leaders.
UCB PharmaMarinus Pharmaceuticals Inc.
Contender1
Focused players with pockets of strength.
GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
Niche3
Specialists in a single segment or region.
Eisai Co. Ltd.Biogen Inc.Pfizer Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Approach in North America, then scale across Dravet Syndrome Therapeutics Market — a $383M beachhead inside a $6.98B market.
Beachhead (SOM)$383Mobtainable near-term
Serviceable (SAM)$2.50Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Antiepileptic Drugs (AEDs)
Best fit — highest urgency & budget in Therapeutic Approach.
Economic buyer77 fit
Cannabidiol-based Therapies
Strong fit — clear ROI and a fast path to value.
End user70 fit
Gene Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Approach in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Approach leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Dravet Syndrome Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation13%
Closed-won7%
$13.2KCAC
$70KLTV
5.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Dravet Syndrome Therapeutics Market is a resilient opportunity — $2.98B by 2033, compounding at 3.7%.
TAM · 2025$2.23Btoday
TAM · 2033$2.98Bforecast
CAGR3.7%2027–2033
Cumulative$23.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.98BTotal addressable market
SAM$1.17BServiceable available market
SOM$190MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.7% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Approach.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Approach moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.98BLarge & growingTAM by 2033 at 3.7% CAGR
$1.17BServiceable nowreachable with today’s model
$190MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.32BBear2.4% CAGR
$2.98BBase3.7% CAGR
$3.81BBull4.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Dravet Syndrome Therapeutics Market — a $4.86B market by 2033. Plan: grow share from 10.4% to 16.2%.
Market size · 2033$4.86Btotal addressable
Market CAGR8.1%2027–2033
Target share16.2%from 10.4% today
Revenue ambition$788Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 16.2% | Ahead |
| Revenue | $486M | $788M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 32.9% | 38.1% | At risk |
| Customer retention | 85.5% | 95.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Approach
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Approach share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Approach leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Dravet Syndrome Therapeutics Market conversation — a $1.77B market you can size, segment and defend in minutes.
Market size · 2033$1.77Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,188+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Approach
Goal Grow share in Therapeutic Approach
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 4 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Zogenix Inc.Greenwich Biosciences (a subsidiary of Jazz Pharmaceuticals)UCB PharmaMarinus Pharmaceuticals Inc.GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)Eisai Co. Ltd.Biogen Inc.Pfizer Inc.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Dravet Syndrome Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Dravet Syndrome Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Draw Latches For Boats Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportDraw Textured Polyester Yarn Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportDrawbench Machine Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportDrawer Basket Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportDrawer Dishwasher Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportDrawer Knobs Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportDrawer Magnet Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportDrawer Minibar Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDrawer Type Circuit Breaker Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportDrawer Warmers Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportDrawing Board Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportDrawing Lubricant Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.